Table 3.

Clinical trials of adult bone marrow autotransplantation in ischaemic heart disease

No.	Bone marrow (BM) cells	Route of administration	Clinical outcome	Follow-up (months)	Ref.
Acute myocardial infarction
10 (5-9 days after injury)	Mononuclear BM cell aspirate 2.1% CD34+, 0.6% CD133+ total 18 million CD34+ cells	Intracoronary, 6-7 injections of 2-3 mL containing 1.5-4 million CD34+ cells each	Increased contractility; reduced hypokinetic area	3	104
20 (4 days after injury) versus 11 control	Mononuclear BM cell aspirate (n=9) 1-7 million CD34+ or blood progenitor cells (n=11) 245 blood million cells	Intracoronary catheter 3 injections of 3 mL each	Increased global LVEF; reduced end-systolic; improved coronary flow reserve	4	105
30 (3-6 days after injury) versus 30 control	Mononuclear BM cell aspirate 4% CD34+, total 3-15 million CD34+ cells	Intracoronary, 4-5 injections of 5 mL each containing 0.6-3 million CD34+ cells	Increased global LVEF; increased systolic wall motion	6	111
Chronic ischaemic heart disease
5	Mononuclear BM cell aspirate	With coronary artery bypass, 11 transendocardial injections of 0.1 mL	Improved coronary perfusion	12	103
6	Selected CD133+ BM cells; total 1.5 million CD133+ cells	With coronary artery bypass, 10 transendocardial injections of 0.2 mL	Improved coronary perfusion; improved global LVEF	6	109
14	Mononuclear BM cell aspirate	With coronary artery bypass	Improved global LVEF; increased cardiac function	10	110
12	Selected CD133+ BM cells; total 1.5 million CD133+ cells	With coronary artery bypass, 10 transendocardial injections of 0.2 mL	Improved local perfusion; improved global LVEF	12	112
10	Mononuclear BM cell aspirate	Endomyocardial catheter injection	Improved LVEF	3	106
14	Mononuclear BM cell aspirate	Endomyocardial catheter injection	Improved LVEF; reduced end systolic volume	2-4	107
8	Mononuclear BM cell aspirate	Endomyocardial catheter injection	Increased wall motion	3	106

LVEF=left ventricular ejection fraction